

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	Number Agreed	4	4	Date Agreed	25/12/2017	2	16/07/2018	2	Recruitment Finished
2	17/EE/0079	220827	CL010_168	Number Agreed	1	1	Date Agreed	31/12/2018	1	04/07/2018	1	Recruitment Finished
3	13/ES/0005	114717	NCRN525 - AZACITIDINE + BSC v PLACEBO + BSC in MDS	Number Agreed	2	2	Date Agreed	31/05/2022	2	27/07/2018	2	Recruitment Finished
4	15/SW/0326	189007	ATLAS: JNJ56021927 (ARN509)	Number Agreed	10	10	Date Agreed	31/08/2018	13	30/07/2018	13	Recruitment Finished
5	16/LO/1222	191705	ATLANTIS Trial	Number Agreed	3	3	Date Agreed	31/07/2018	1	31/07/2018	1	Recruitment Finished
6	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	Number Agreed	3	3	Date Agreed	31/12/2018	4	14/09/2018	4	Recruitment Finished
7	17/SC/0055	219468	AIN457 Paed	Number Agreed	2	2	Date Agreed	07/11/2018	3	28/09/2018	3	Recruitment Finished
8	16/SC/0530	213306	Ketocal 2.5:1 LQ tolerance trial	Number Agreed	2	2	Date Agreed	30/09/2018	1	31/08/2018	1	Recruitment Finished
9	17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo BioPharma	Number Agreed	1	1	Date Agreed	30/12/2018	4	05/10/2018	4	Recruitment Finished
10	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	31/10/2018	3	08/10/2018	3	Recruitment Finished
11	16/LO/0581	194313	CANC 5246	Number Agreed	1	1	Date Agreed	15/10/2018	2	11/10/2018	2	Recruitment Finished
12	14/SC/1366	135118	NCRN - 3131: EPOCH TheraSphere in Metastatic Colorectal Carcinoma of the Liver (TS102)	Number Agreed	3	3	Date Agreed	30/09/2018	3	26/10/2018	3	Recruitment Finished
13	18/NW/0015	233850	CONSTANT	Number Agreed	50	50	Date Agreed	28/09/2018	65	31/10/2018	62	Recruitment Finished
14	17/LO/1656	229212	CO39722 - Cobimetinib and atezolizumab v's pembrolizumab in melanoma	Number Agreed	3	3	Date Agreed	31/10/2018	2	07/11/2018	2	Recruitment Finished
15	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	Number Agreed	2	2	Date Agreed	30/11/2018	0	14/11/2018	0	Recruitment Finished
16	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	Number Agreed	5	5	Date Agreed	30/11/2018	5	14/11/2018	5	Recruitment Finished
17	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	Number Agreed	4	4	Date Agreed	30/06/2021	0	08/12/2018	0	Recruitment Finished
18	15/NW/0009	160002	MCRN3127 (20130173)	Number Agreed	3	3	Date Agreed	31/01/2019	5	13/12/2018	5	Recruitment Finished
19	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	2	2	Date Agreed	30/11/2018	0	15/10/2018	0	Withdrawn By Host
20	18/LO/0126	239586	Phase 1 study of WVE-210201 in patients with DMD	Number Agreed	1	1	Date Agreed	21/12/2018	1	20/12/2018	1	Recruitment Finished
21	17/EM/0355	229043	SPIRIT 2 #	Number Agreed	4	4	Date Agreed	28/02/2019	0	28/02/2019	0	Withdrawn By Host
22	17/EE/0437	233853	AQUILA (54767414SMM3001)	Number Agreed	2	2	Date Agreed	13/12/2019	4	07/03/2019	4	Recruitment Finished
23	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	11/03/2019	2	11/03/2019	2	Recruitment Finished
24	18/LO/0378	234232	PIONEER III	Number Agreed	12	12	Date Agreed	30/06/2019	6	15/03/2019	6	Recruitment Finished
25	17/SC/0228	219158	Javelin Head and Neck	Number Agreed	4	4	Date Agreed	08/04/2021	3	18/12/2018	3	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
26	18/SW/0050	235126	A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC	Number Agreed	1	1	Date Agreed	30/04/2019	1	02/04/2019	1	Recruitment Finished
27	17/NI/0096	225743	HOPE-1	Number Agreed	3	3	Date Agreed	30/04/2019	3	29/04/2019	3	Recruitment Finished
28	14/LO/0566	145475	CANC - 3490 OLYMPIA	Number Agreed	3	3	Date Agreed	30/04/2019	30	30/04/2019	30	Recruitment Finished
29	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	Number Agreed	2	2	Date Agreed	31/05/2019	1	13/05/2019	1	Recruitment Finished
30	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	Number Agreed	3	3	Date Agreed	30/06/2019	2	31/05/2019	2	Recruitment Finished